CompletedNCT00811941
Long-term nalmefene safety for alcohol dependence
About this title
Read the official source — NCT00811941Researchers compared Nalmefene and placebo, tracking side effects to assess safety and tolerability in people with alcohol dependence.
Medication studyAges 18+Multiple countriesMental health
Understand this study
What did researchers investigate?
Researchers compared Nalmefene and placebo, tracking side effects to assess safety and tolerability in people with alcohol dependence.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Litoměřice and 59 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 665
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Czechia, Estonia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00811941
- Official title
Show the full official title
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Litoměřice, Czechia · Lnáře, Czechia · Prague, Czechia
48 more locations
- Ústí nad Labem, Czechia
- Pärnu, Estonia
- Tallinn, Estonia
- Vorumaa, Estonia
- Võru, Estonia
- Budapest, Hungary
- Daugavpils, Latvia
- Jelgava, Latvia
- Riga, Latvia
- Sigulda, Latvia
- Kaunas, Lithuania
- Bełchatów, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Krakow, Poland
- Leszno, Poland
- Lodz, Poland
- Lublin, Poland
- Piekary Śląskie, Poland
- Skorzewo, Poland
- Starogard Gdański, Poland
- Swicie n/Wisla, Poland
- Szczecin, Poland
- Torun, Poland
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Voronezh, Russia
- Banska Bysterica, Slovakia
- Krupina, Slovakia
- Nitra, Slovakia
- Rimavská Sobota, Slovakia
- Chernihiv, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Ternopil, Ukraine
- Birmingham, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Reading, United Kingdom
- Czechia
- Russia
Questions about this study
What did researchers investigate?
Researchers compared Nalmefene and placebo, tracking side effects to assess safety and tolerability in people with alcohol dependence.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Nalmefene.
Who was this study for?
Listed age limits: from 18 years.
Want to explore more studies?
Explore studiesRelated studies
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Nalmefene and relapse outcomes in alcohol dependence